Country: Canada
Language: English
Source: Health Canada
DARUNAVIR (DARUNAVIR ETHANOLATE)
PATRIOT A DIVISION OF JANSSEN INC
J05AE10
DARUNAVIR
75MG
TABLET
DARUNAVIR (DARUNAVIR ETHANOLATE) 75MG
ORAL
480
Prescription
HIV PROTEASE INHIBITORS
Active ingredient group (AIG) number: 0151656004; AHFS:
APPROVED
2012-11-19
_ _ _Page 1 of 78 _ PRODUCT MONOGRAPH PR PAT-DARUNAVIR darunavir tablets 75 mg, 150 mg, 400 mg, 600 mg, 800 mg (as darunavir ethanolate) Human Immunodeficiency Virus (HIV) Protease Inhibitor Patriot, a division of Janssen Inc. 19 Green Belt Drive Toronto, Ontario M3C 1L9 Date of Preparation: November 30, 2012 www.patriot-canada.ca Submission Control No: 159996 © JANSSEN Inc. 2012 All trademarks used under license. Draft Date: Oct 26, 2012 _ _ _Page 2 of 78 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ....................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 4 WARNINGS AND PRECAUTIONS ......................................................................................... 4 ADVERSE REACTIONS ........................................................................................................... 9 DRUG INTERACTIONS ......................................................................................................... 20 DOSAGE AND ADMINISTRATION ..................................................................................... 32 OVERDOSAGE ....................................................................................................................... 35 ACTION AND CLINICAL PHARMACOLOGY ................................................................... 35 STORAGE AND STABILITY ................................................................................................. 38 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................... 38 PART II: SCIENTIFIC INFORMATION .............................................................................. 40 PHARMACEUTICAL INFORMATION ............................. Read the complete document